Tesamorelin is an FDA-approved GHRH analogue studied primarily for reducing visceral adipose tissue. It is one of the most potent growth hormone secretagogues available.
Stimulates GH release from the pituitary. The stabilised structure of Tesamorelin makes it more resistant to enzymatic degradation than native GHRH, extending its activity.
Fluid retention, joint pain, and insulin resistance at higher doses. Contraindicated in active malignancies.
1–2 mg SubQ daily. Rotate injection sites. Cycle 12–16 weeks.